Related news from
Wed, 01 May 2024 14:00:15 +0000	Can DexCom, Inc.'s (NASDAQ:DXCM) ROE Continue To Surpass The Industry Average? While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Tue, 30 Apr 2024 19:03:00 +0000	Dexcom Stock Continues To Post Very Healthy Profits, Returns Dexcom stock shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
Tue, 30 Apr 2024 16:45:09 +0000	Here is Why Growth Investors Should Buy DexCom (DXCM) Now DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Tue, 30 Apr 2024 16:35:00 +0000	Ecolab (ECL) Q1 Earnings Surpass Estimates, Margins Rise Ecolab's (ECL) robust performance across the majority of its segments drives its first-quarter sales despite business challenges.
Tue, 30 Apr 2024 16:26:00 +0000	QIAGEN (QGEN) Q1 Earnings Top Estimates, Margins Expand QIAGEN (QGEN) Q1 results are driven by solid growth in consumables and ongoing higher instruments placements.
Tue, 30 Apr 2024 14:31:05 +0000	DexCom, Inc. (NASDAQ:DXCM) Q1 2024 Earnings Call Transcript DexCom, Inc. (NASDAQ:DXCM) Q1 2024 Earnings Call Transcript April 25, 2024 DexCom, Inc. beats earnings expectations. Reported EPS is $0.32, expectations were $0.27. DexCom, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, welcome to the Dexcom […]
Tue, 30 Apr 2024 13:00:12 +0000	DexCom, Inc. (DXCM) Is a Trending Stock: Facts to Know Before Betting on It DexCom (DXCM) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Mon, 29 Apr 2024 13:45:12 +0000	Here's Why DexCom (DXCM) is a Strong Growth Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Sat, 27 Apr 2024 14:18:13 +0000	DexCom First Quarter 2024 Earnings: Beats Expectations DexCom ( NASDAQ:DXCM ) First Quarter 2024 Results Key Financial Results Revenue: US$921.0m (up 24% from 1Q 2023). Net...
Fri, 26 Apr 2024 20:11:10 +0000	Dexcom Plummets After Raising Its Sales Guidance For The Year — But Not Enough Dexcom stock plunged Friday after the company raised its sales outlook for the year, but not enough to satisfy investors.
Fri, 26 Apr 2024 19:09:22 +0000	ABT, DHR, DXCM: Which “Strong Buy” Healthcare Stock Has More Upside? The healthcare scene is home to some pretty defensive companies that aren’t exactly shying away from medical innovation. With the following Strong-Buy-rated health stocks (ABT, DHR, and DXCM), investors may just be able to get growth, relative defensiveness, and decent multiples as we head into May 2024. Undoubtedly, investors may wish to come for the underestimated growth and stay for their ability to move higher, even as the market tides turn against most stocks in the market. Therefore, in th
Fri, 26 Apr 2024 11:29:00 +0000	DexCom (DXCM) Q1 Earnings Beat, Strong CGM Demand Continues DexCom's (DXCM) first-quarter 2024 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
Fri, 26 Apr 2024 11:09:11 +0000	Q1 2024 Dexcom Inc Earnings Call Q1 2024 Dexcom Inc Earnings Call
Fri, 26 Apr 2024 05:30:12 +0000	DexCom (DXCM) Q1 2024 Earnings Call Transcript DXCM earnings call for the period ending March 31, 2024.
Fri, 26 Apr 2024 05:03:27 +0000	Decoding DexCom Inc (DXCM): A Strategic SWOT Insight Unveiling the Financial Fortitude and Market Dynamics of DexCom Inc (DXCM)
Thu, 25 Apr 2024 22:29:36 +0000	Dexcom's profit beats estimates on strong glucose monitor demand Dexcom beat Wall Street expectations for first-quarter profit on Thursday, helped by strong demand for a new version of its continuous glucose monitors, but its shares slid 7% after the bell as annual sales forecast was largely below estimates. The company and rival Abbott currently dominate the market for continuous glucose monitors — the devices that track blood glucose levels every few minutes without the need for finger stick tests. Dexcom's total revenue rose 24% to $921 million for the three months ended March 31, beating analysts' average estimate of $909.24 million, according to LSEG data.
Thu, 25 Apr 2024 22:00:09 +0000	DexCom (DXCM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates While the top- and bottom-line numbers for DexCom (DXCM) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Thu, 25 Apr 2024 21:43:42 +0000	DexCom Inc (DXCM) Surpasses Analyst Revenue Forecasts with Strong Q1 2024 Performance Revenue Growth and Strategic Advances Highlight DexCom's First Quarter Achievements
Thu, 25 Apr 2024 20:03:00 +0000	Dexcom Reports First Quarter 2024 Financial Results SAN DIEGO, April 25, 2024--DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2024.
Wed, 24 Apr 2024 13:30:10 +0000	Wall Street Bulls Look Optimistic About DexCom (DXCM): Should You Buy? Based on the average brokerage recommendation (ABR), DexCom (DXCM) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?